Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 2/2015

01-11-2015 | Clinical Study

The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis

Authors: Wei Wei, Xin Chen, Ximeng Ma, Dawei Wang, Zongze Guo

Published in: Journal of Neuro-Oncology | Issue 2/2015

Login to get access

Abstract

The goal of this meta-analysis was to identify the temozolomide (TMZ) regimen with optimal efficacy and tolerance for treatment of recurrent high-grade glioma (HGG). The PubMed and EMBASE databases were searched from the earliest records to February 2015, which identified 33 studies with 1760 participants that met the inclusion criteria. The standard schedule and three most common dose-dense regimens of TMZ therapy for recurrent HGG were included in this meta-analysis. The schedule of 7 days on/7 days off for the treatment of grade IV gliomas was significantly superior to the standard regimen with respect to progression-free survival at 6 months (34.8 %; 95 % confidence interval (CI) 27.0–43.4 %) and 12 months (15.5 %; 95 % CI 10.7–21.8 %). For grade III gliomas, this regimen conveyed a significantly greater overall survival (OS) rate at 12 months (79.0 %; 95 % CI 56.2–91.7 %), as compared to the standard schedule. Also, the 21 days on/7 days off regimen had significantly longer OS rates at 6 months (73.6 %; 95 % CI 63.4–81.8 %) and 12 months (40.6 %; 95 % CI 32.6–48.6 %) than the standard regimen for grade IV gliomas. In addition, the standard schedule showed a significantly higher clinical benefit rate than the 7 days on/7 days off and 21 days on/7 days off regimens. However, the grade 3–4 toxicity rate of lymphopenia of the standard schedule was 76.5 % (95 % CI 45.5–92.7 %), which was the highest among the four regimens. Recurrent HGG patients receiving personalized treatment should be closely followed up, especially those with concurrent hematological diseases.
Literature
1.
Kong DS, Lee JI, Kim WS et al (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16:1117–1121PubMed
2.
3.
Easaw JC, Mason WP, Perry J et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 18:e126–e136PubMedCentralCrossRefPubMed
4.
Gilbert MR (2006) Advances in the treatment of primary brain tumors: dawn of a new era? Curr Oncol Rep 8:45–49CrossRefPubMed
5.
Stupp R, Mason WP, Van Den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed
6.
7.
Terasaki M, Tokutomi T, Shigemori M (2009) Salvage therapy with temozolomide for recurrent or progressive high-grade gliomas refractory to ACNU [1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride]. Mol Med Rep 2:417–421. doi:10.​3892/​mmr_​00000115 PubMed
8.
9.
10.
11.
12.
Newlands ES, Stevens MF, Wedge SR et al (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35–61CrossRefPubMed
13.
Tisdale MJ (1987) Antitumor imidazotetrazines–XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36:457–462CrossRefPubMed
14.
Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388–2399CrossRefPubMed
15.
Kurzen H, Schmitt S, Näher H et al (2003) Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14:515–522CrossRefPubMed
16.
Kim JT, Kim J-S, Ko KW et al (2006) Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16:33–39PubMed
17.
Klement G, Huang P, Mayer B et al (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8:221–232PubMed
18.
19.
Tolcher A, Gerson S, Denis L et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004–1011PubMedCentralCrossRefPubMed
20.
21.
Galldiks N, Berhorn T, Blau T et al (2013) “One week on-one week off”: efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. J Neurooncol 112:209–215. doi:10.​1007/​s11060-013-1048-z CrossRefPubMed
22.
23.
Macdonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMed
24.
Colditz GA, Burdick E, Mosteller F (1995) Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary. Am J Epidemiol 142:371–382PubMed
25.
Higgins J, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed
26.
Harris R, Bradburn M, Deeks J et al (2008) Metan: fixed- and random-effects meta-analysis. Stata J 8:3–28
27.
Hassler M, Micksche M, Stockhammer G et al (2006) Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study. Wien Klin Wochenschr 118:230–238. doi:10.​1007/​s00508-006-0576-3 CrossRefPubMed
28.
29.
30.
Brandes AA, Ermani M, Basso U et al (2002) Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure a phase II study. Oncology 63:38–41CrossRefPubMed
31.
Chinot OL, Honore S, Dufour H et al (2001) Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19:2449–2455PubMed
32.
33.
Brandes AA, Ermani M, Basso U et al (2001) Temozolomide as a second-line systemic regimen in recurrent high-grade glioma, a phase II study. Ann Oncol 12:255–257CrossRefPubMed
34.
Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma. Ann Oncol 12:259–266CrossRefPubMed
35.
Paulsen F, Hoffmann W, Becker G et al (1999) Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. J Cancer Res Clin Oncol 125:411–418CrossRefPubMed
36.
Bower M, Newlands ES, Bleehen NM et al (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40:484–488CrossRefPubMed
37.
38.
Teixeira MM, Garcia I, Portela I et al (2002) Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution. Int J Clin Pharmacol Res 22:19–22PubMed
39.
40.
Perry JR, Rizek P, Cashman R et al (2008) Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue” approach. Cancer 113:2152–2157. doi:10.​1002/​cncr.​23813 CrossRefPubMed
41.
42.
Strik HM, Buhk JH, Wrede A et al (2008) Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. Mol Med Rep 1:863–867. doi:10.​3892/​mmr_​00000042 PubMed
43.
44.
45.
Neyns B, Chaskis C, Joosens E et al (2008) A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest 26:269–277. doi:10.​1080/​0735790070170839​3 CrossRefPubMed
46.
47.
48.
49.
50.
51.
Wick W, Steinbach JP, Kuker WM et al (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115CrossRefPubMed
52.
Weller M, Tabatabai G, Kästner B et al (2015) MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR Trial. Clin Cancer Res 21:2057–2064CrossRefPubMed
53.
Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003CrossRefPubMed
54.
Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354CrossRefPubMed
55.
Krex D, Klink B, Hartmann C et al (2007) Long-term survival with glioblastoma multiforme. Brain 130:2596–2606CrossRefPubMed
56.
57.
Weiler M, Hartmann C, Wiewrodt D et al (2010) Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys 77:670–676CrossRefPubMed
58.
Chinot OL, Barrié M, Fuentes S et al (2007) Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25:1470–1475CrossRefPubMed
59.
Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436CrossRefPubMed
60.
Bertolini F, Paul S, Mancuso P et al (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342–4346PubMed
61.
Emmenegger U, Man S, Shaked Y et al (2004) A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64:3994–4000CrossRefPubMed
62.
Bocci G, Francia G, Man S et al (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100:12917–12922PubMedCentralCrossRefPubMed
Metadata
Title
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis
Authors
Wei Wei
Xin Chen
Ximeng Ma
Dawei Wang
Zongze Guo
Publication date
01-11-2015
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2015
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-015-1920-0

Other articles of this Issue 2/2015

Journal of Neuro-Oncology 2/2015 Go to the issue

Clinical Study

Socio-economic characteristics of patients with glioblastoma multiforme

Clinical Study

Safety of intra-cerebrospinal fluid chemotherapy in onco-haematological patients: a retrospective analysis of 627 interventions

Clinical Study

Accuracy of Tokuhashi score system in predicting survival of lung cancer patients with vertebral metastasis

Clinical Study

Location of brain tumor intersecting white matter tracts predicts patient prognosis

Clinical Study

Brainstem metastases treated with stereotactic radiosurgery: safety, efficacy, and dose response

Clinical Study

Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease